Mode
Text Size
Log in / Sign up

Intimate partner violence triples cervical cancer risk in meta-analysis of adult womenIntimate partner violence linked to higher risk of cervical cancer

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider IPV exposure as a possible risk factor for cervical cancer, but recognize evidence is preliminary and not causal.

This systematic review and meta-analysis examined the association between intimate partner violence (IPV) and cervical cancer risk in adult women (≥18 years) with documented IPV exposure. The primary outcome was cancer risk, with secondary outcomes including precancerous outcomes.

Pooled analysis from available studies showed a significantly increased odds of cervical cancer among women exposed to IPV (OR 3.00, 95% CI 2.05-4.38; I² = 0%). Additionally, 32.2% of women with cancer reported a lifetime history of IPV.

The authors note several limitations: the existing evidence is limited and heterogeneous, there is a scarcity of high-quality longitudinal studies, and methodological variability across studies was observed. These factors mean the findings are preliminary and insufficient to establish a causal link between IPV and cervical cancer.

Clinicians should be aware of this possible association, but the evidence does not yet support changes to screening or prevention guidelines. Further prospective research is needed to clarify the relationship and underlying mechanisms.

How this fits prior evidence

This meta-analysis extends prior evidence on cervical cancer risk factors by identifying IPV as a potential contributor. Previous coverage highlighted the role of NLRP3 inflammasome in immune evasion and the prognostic value of lymphocyte-to-monocyte ratio, but did not address psychosocial exposures. The finding of a tripled odds of cervical cancer with IPV exposure (OR 3.00) contrasts with the lack of such association in earlier work and addresses a gap in understanding non-biological risk factors. However, the limited longitudinal data and heterogeneity noted here echo cautions from prior coverage on FAPI PET and LMR studies regarding the need for prospective validation.

Living in an abusive relationship can have deep, lasting effects on a person's health. New data suggests that the physical and emotional toll of intimate partner violence (IPV) may be linked to a much higher risk of developing cervical cancer.

Researchers looked at existing data and found that women who experienced IPV had three times the odds of being diagnosed with cervical cancer compared to those who did not. Additionally, about 32% of women already diagnosed with cancer reported a history of intimate partner violence during their lives.

While these numbers show a strong connection, it is important to note that the evidence is still limited and varied. Because there are very few high-quality long-term studies available right now, we cannot say for certain that one causes the other. The findings highlight how critical it is to support survivors of violence with comprehensive care.

What this means for you:
Women who experience intimate partner violence have three times the odds of developing cervical cancer.

Common questions

How does intimate partner violence affect cancer risk?

Women who have experienced intimate partner violence (IPV) show a pooled odds ratio of 3.00 for cervical cancer. This means these women are three times more likely to develop the cancer than those who have not experienced such violence.

How common is this experience among women with cancer?

The data shows that 32.2% of women already diagnosed with cervical cancer reported having a lifetime history of intimate partner violence (IPV).

Does this mean violence causes cancer?

While the link is strong, researchers cannot say for sure if one causes the other yet. The current evidence is limited and varied, and there is a shortage of high-quality long-term studies to prove a direct cause.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
ABSTRACT Background: Despite its high prevalence and established impact on women's health, the long-term biological effects of Intimate Partner Violence (IPV) remain poorly understood. In particular, its potential role in increasing cancer risk has received limited attention. This review examines whether IPV may be associated with elevated cancer risk in women. Methods: We conducted a systematic review and meta-analysis in accordance with PRISMA and MOOSE guidelines to evaluate whether IPV may be associated with cancer risk. Eligible studies included adult women ([≥]18 years) with documented IPV exposure and cancer or precancerous outcomes. We searched PubMed, Web of Science, Scopus, and Google Scholar for articles published from 2000 to 2025. Study quality was assessed using the Newcastle-Ottawa Scale (NOS). A random-effects meta-analysis was performed on longitudinal studies reporting adjusted risk estimates. Results: Thirteen studies were included in the qualitative synthesis, but only two met criteria for meta-analysis, both reporting on cervical cancer. The pooled odds ratio was 3.00 (95% CI: 2.05 - 4.38; I2 = 0%). A separate pooled prevalence analysis of six retrospective studies showed that 32.2% of women with cancer reported a lifetime history of IPV. Study quality ranged from low to high. Conclusions: This review underscores the limited and heterogeneous nature of the existing evidence on IPV as a potential cancer risk factor. While preliminary findings suggest a possible association, particularly with cervical cancer, the scarcity of high-quality longitudinal studies and the methodological variability in the studies reviewed prevent definitive conclusions regarding causal linkage. Further research, particularly prospective and mechanistic studies, is needed to clarify the relationship between IPV and oncogenesis across different cancer types and to identify underlying biological pathways.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.